바로가기 메뉴
본문 바로가기
푸터 바로가기
TOP

 

교수진

Judy Juyoung Shin Professor

전공Pharmacoepidemiology, Social Pharmacy
주소20-322
연락처880-1547
이메일shin.jy@snu.ac.kr
Education

2008-2012 College of Medicine Seoul National University (Ph.D.)

2005-2008 School of Public Health, Seoul National University (M.P.H)

2000-2005 College of Pharmacy, Seoul National University (B.Pharm)

Professional Experiance

2016-2026. Professor, Department Head, School of Pharmacy, SungKyunKwan University (SKKU)

2015~2016. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (Canada)

2012~2015. Team leader, Senior Researcher, Office of Drug Utilization Review, Korea Institute of Drug Safety and Risk Management

Description of Research Field
– Pharmacoepidemiology
– Pharmacovigilance
– Real world data and real word evidence for regulatory science
Representative Publication
  1. Shin, JY; Park, MJ; Lee, SH; Choi, SH; Kim, MH; Choi, NK; Lee, J; Park, BJ. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351:h3517. (IF=43.0, Top 1.4%) (1st author)
  2. Shin, JY; Roughead, EE; Park, BJ; Pratt, NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 2016; 353: j2550. (IF=43.0, Top 1.4%) (1st author)
  3. Yoon, D; Lee, JH; Lee, H; Shin, JY. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. BMJ 2021;372:m4931. (IF=43.0, Top 1.4%) (Corresponding author)
  4. Choi, EY; Cho, Y; Oh, J; Choi, A; Kim, H; Shin, JY. Oral Corticosteroid Use During Pregncy and the Risk of Gestational Diabetes. JAMA Intern Med. 2025. (IF=23.3, Top 2%) (Corresponding author)
  5. Hong, B; Lee, H; Jung, K; Rhee, SY; Yon, DK; Shin, JY. Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study. BMJ 2025;391:e085196. (IF=43.0, Top 1.4%) (Corresponding author)
  6. Hong, B; Bea, S; Ko, HY; Kim, WJ; Cho, YM; Shin, JY. Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study. Ann Intern Med 2024;177(10):1319-1329. (IF=15.4, Top 2.6%) (Corresponding author)
  7. Bea, S; Jeong, HE; Park, S; Yu, OHY; Chang, Y; Cho, J; Sinn, DH; Cho, YM; Shin, JY. Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study. Gut 2023;72(5):1020-1022. (IF=26.2, Top 2.4%) (Corresponding author)
  8. Bea, S; Ko, HY; Bae, JH; Cho, YM; Chang, Y; Ryu, S; Byrne, CD; Shin, JY. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut 2025;74(2):284-294. (IF=26.2, Top 2.4%) (Corresponding author)
  9. Noh, Y; Jeong, HE; Choi, A; Choi, EY; Pasternak, B; Nordeng, H; Bliddal, M; Man, KKC; Wong, ICK; Yon, DK; Shin, JY. Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children. JAMA Pediatr. 2023;177(3):267-277.